In summary, our study demonstrates that IL-22 and ILC3s can prevent excess inflammation, reduce bacterial burden, improve lipid metabolism and prolong the survival of T2DM mice infected with Mtb. Further understanding of these mechanisms and human studies can help to treat TB patients with T2DM. This evidence concerns the gene IL22 and type 2 diabetes mellitus.